"Chairman Shin Dong-hwa: 'Leading Technology and Market in the Field of NK Cells to Enhance National Competitiveness'"

"NKCL Bio Group (NKCL Bio Group Co., Ltd.) has won the 'Minister of Food and Drug Safety Award' in the R&D Management category at the 2023 National Empathy Management Awards. (Photo: NKCL Bio Group Co., Ltd.)"

NKCL Bio Group (Chairman Shin Dong-hwa) announced on the 21st that they have been selected as the recipient of the 'Minister of Food and Drug Safety Award' in the 'Research and Development (R&D) Management' category at the <2023 National Empathy Management Awards> hosted by DongA Ilbo, recognizing their successful management achievements through 'empathy' and 'communication'.

NKCL Bio Group, which has consistently contributed to the development of the bio industry in South Korea, plans to continue its dedication to R&D through ongoing investments. This commitment extends not only to the domestic market but also to the global arena, focusing on the development of diverse technologies utilizing Natural Killer Cells (NK Cells).

Chairman Shin Dong-hwa of NKCL Bio Group expressed, "Winning the 'Minister of Food and Drug Safety Award' in the R&D Management category as a bio company brings us immense honor. We will lead the field of NK Cells by developing next-generation anticancer therapies utilizing these vital immune system components and establishing a GMP automation system for their mass production. Through this, we aim to enhance national competitiveness and contribute to the growth potential of the Korean economy."

Furthermore, under the strategy of targeting the global market with a more scalable model for the automated cultivation system, NKCL Bio Group has introduced the 'RK-NKTM ACS,' a single-user automated cultivation device for NK Cells. As a result, NKCL anticipates that significant bio sales will be generated through the 'RK-NKTM ACS' in 2023.

Chairman Shin Dong-hwa explained, "NKCL Bio Group has recently achieved the technological capability to regulate cell activity, including immune suppression, tumor variability, and the diversity of cancer manifestations, taking into account the complexities of cancer. Unlike conventional treatment methods, this allows us to adjust cell activity to suit the patient."

In pursuit of this goal, NKCL Bio Group is making efforts to establish a systematic treatment system through its internally developed personalized immune assessment system. Moreover, the company is rapidly advancing various business expansions and initiatives, including ongoing Memoranda of Understanding (MOUs), the establishment of overseas subsidiaries (in the United States, Japan, Indonesia, China, and Vietnam), and business endeavors.

The <2023 National Empathy Management Awards> ceremony took place on August 24th at the Grand Ballroom of The Plaza Hotel in Jung-gu, Seoul. The event was sponsored by the Ministry of Economy and Finance, the Ministry of Science, ICT, and Future Planning, the Ministry of Public Administration and Security, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, the Ministry of Environment, the Ministry of Employment and Labor, the Ministry of SMEs and Startups, the Ministry of Food and Drug Safety, and the Coexistence Growth Commission.